Page 3«..2345..1020..»

Vistin Pharma ASA: Invitation to Q4 2020 conference call

By Dr. Matthew Watson

Oslo, Norway, 12 February 2020

Link:
Vistin Pharma ASA: Invitation to Q4 2020 conference call

To Read More: Vistin Pharma ASA: Invitation to Q4 2020 conference call
categoriaGlobal News Feed commentoComments Off on Vistin Pharma ASA: Invitation to Q4 2020 conference call | dataFebruary 14th, 2021
Read All

Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine

By Dr. Matthew Watson

NEW YORK and MAINZ, GERMANY, February 12, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has exercised its option for an additional 100 million doses of the Pfizer-BioNTech COVID-19 vaccine. This brings the total number of doses to be supplied by the companies to the U.S. government to 300 million.

Read the original here:
Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine

To Read More: Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine
categoriaGlobal News Feed commentoComments Off on Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine | dataFebruary 14th, 2021
Read All

Quotient Limited Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

By Dr. Matthew Watson

JERSEY, Channel Islands, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today announced the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18.

Continue reading here:
Quotient Limited Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

To Read More: Quotient Limited Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
categoriaGlobal News Feed commentoComments Off on Quotient Limited Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference | dataFebruary 14th, 2021
Read All

Vericel Announces Termination of Shareholder Rights Agreement

By Dr. Matthew Watson

CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its Board of Directors unanimously approved the termination of the Company’s shareholder rights agreement, commonly referred to as a “poison pill”, which was originally scheduled to expire on August 15, 2021. The shareholder rights agreement was amended to accelerate the expiration date to February 11, 2021, effectively terminating the plan as of that date.

Go here to read the rest:
Vericel Announces Termination of Shareholder Rights Agreement

To Read More: Vericel Announces Termination of Shareholder Rights Agreement
categoriaGlobal News Feed commentoComments Off on Vericel Announces Termination of Shareholder Rights Agreement | dataFebruary 14th, 2021
Read All

Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021

By Dr. Matthew Watson

Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET

Read more:
Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021

To Read More: Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021
categoriaGlobal News Feed commentoComments Off on Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021 | dataFebruary 14th, 2021
Read All

Cronos Group Inc. to Hold 2020 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2021

By Dr. Matthew Watson

TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) will hold its 2020 Fourth Quarter and Full-year Earnings Conference Call on Friday, February 26, 2021 at 8:30 a.m. EST. Cronos Group’s senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks.

Follow this link:
Cronos Group Inc. to Hold 2020 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2021

To Read More: Cronos Group Inc. to Hold 2020 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2021
categoriaGlobal News Feed commentoComments Off on Cronos Group Inc. to Hold 2020 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2021 | dataFebruary 14th, 2021
Read All

Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day

By Dr. Matthew Watson

AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Citi’s 2021 Virtual Immuno-Oncology Day Conference being held virtually February 17-18, 2021.

Go here to see the original:
Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day

To Read More: Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day
categoriaGlobal News Feed commentoComments Off on Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day | dataFebruary 14th, 2021
Read All

Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering

By Dr. Matthew Watson

TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has closed its previously announced bought deal prospectus offering of 46,000,000 units (“Units”) at a price of $0.50 per Unit for aggregate gross proceeds of $23,000,000 (the “Offering”), which includes the exercise in full of the 15% over-allotment option. The syndicate of underwriters was led by Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (together, the "Underwriters"). The Units were offered and sold by way of a short form prospectus filed with the securities commissions in each of the provinces of Canada, other than Québec.

Read the original here:
Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering

To Read More: Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering
categoriaGlobal News Feed commentoComments Off on Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering | dataFebruary 14th, 2021
Read All

Delisting of AS „Grindeks” shares from the Baltic Main list

By Dr. Matthew Watson

Delisting of AS „Grindeks” shares from the Baltic Main list

Read this article:
Delisting of AS „Grindeks” shares from the Baltic Main list

To Read More: Delisting of AS „Grindeks” shares from the Baltic Main list
categoriaGlobal News Feed commentoComments Off on Delisting of AS „Grindeks” shares from the Baltic Main list | dataFebruary 14th, 2021
Read All

Tauriga Sciences Inc. to Commence Development of its 1st Full Spectrum CBD Infused Edibles Product Line

By Dr. Matthew Watson

NEW YORK, NY , Feb. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as an ongoing Pharmaceutical Development initiative, today announced that it has commenced development of its 1st full spectrum Cannabidiol (“CBD”) infused edibles product line.  The Company plans to develop this above referenced product line, with the following attributes: Kosher Certified, Halal Certified, Vegan Formulation, Dairy-Free, Infused with Full Spectrum Hemp Extract (“Full Spectrum”), All-Natural Flavors, Sugar Free/Diabetic Friendly Version(s), and Full Adherence to U.S. Federal Laws & Regulations.  The Company expects to provide concrete details about this proposed full spectrum product line within the near term.

Read the rest here:
Tauriga Sciences Inc. to Commence Development of its 1st Full Spectrum CBD Infused Edibles Product Line

To Read More: Tauriga Sciences Inc. to Commence Development of its 1st Full Spectrum CBD Infused Edibles Product Line
categoriaGlobal News Feed commentoComments Off on Tauriga Sciences Inc. to Commence Development of its 1st Full Spectrum CBD Infused Edibles Product Line | dataFebruary 14th, 2021
Read All

New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three…

By Dr. Matthew Watson

In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results of ABO-102 in MPS IIIA and ABO-101 in MPS IIIB continue to show dose-dependent and sustained reductions in disease-specific biomarkers, denoting clear biologic effects

More:
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three...

To Read More: New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three…
categoriaGlobal News Feed commentoComments Off on New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three… | dataFebruary 14th, 2021
Read All

Trading in Novo Nordisk shares by board members, executives and associated persons on 11-12 February 2021

By Dr. Matthew Watson

Bagsværd, Denmark, 12 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Continued here:
Trading in Novo Nordisk shares by board members, executives and associated persons on 11-12 February 2021

To Read More: Trading in Novo Nordisk shares by board members, executives and associated persons on 11-12 February 2021
categoriaGlobal News Feed commentoComments Off on Trading in Novo Nordisk shares by board members, executives and associated persons on 11-12 February 2021 | dataFebruary 14th, 2021
Read All

Radius Health, Inc. Provides Abaloparatide Business Update

By Dr. Matthew Watson

BOSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a business update on the abaloparatide global business. Progress was made, and continues to be made, across the following areas.

Read more:
Radius Health, Inc. Provides Abaloparatide Business Update

To Read More: Radius Health, Inc. Provides Abaloparatide Business Update
categoriaGlobal News Feed commentoComments Off on Radius Health, Inc. Provides Abaloparatide Business Update | dataFebruary 14th, 2021
Read All

Tauriga Sciences, Inc. Now Configured to Accept the Following Cryptocurrencies as Payment Options on Its E-Commerce Platform: Bitcoin (BTC), Etherium…

By Dr. Matthew Watson

The rest is here:
Tauriga Sciences, Inc. Now Configured to Accept the Following Cryptocurrencies as Payment Options on Its E-Commerce Platform: Bitcoin (BTC), Etherium...

To Read More: Tauriga Sciences, Inc. Now Configured to Accept the Following Cryptocurrencies as Payment Options on Its E-Commerce Platform: Bitcoin (BTC), Etherium…
categoriaGlobal News Feed commentoComments Off on Tauriga Sciences, Inc. Now Configured to Accept the Following Cryptocurrencies as Payment Options on Its E-Commerce Platform: Bitcoin (BTC), Etherium… | dataFebruary 14th, 2021
Read All

Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the…

By Dr. Matthew Watson

Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial reduction in baseline corticosteroid use

See the original post here:
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the...

To Read More: Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the…
categoriaGlobal News Feed commentoComments Off on Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the… | dataFebruary 14th, 2021
Read All

FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced…

By Dr. Matthew Watson

View original post here:
FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced...

To Read More: FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced…
categoriaGlobal News Feed commentoComments Off on FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced… | dataFebruary 14th, 2021
Read All

Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares

By Dr. Matthew Watson

Nes Ziona, Israel, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced the closing of its previously announced offering of 2,296,107 ordinary shares, par value NIS 0.40 per share, of the Company at a price to the public of $20.00 per ordinary share, less underwriting discounts and commissions.

Read the original here:
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares

To Read More: Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
categoriaGlobal News Feed commentoComments Off on Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares | dataFebruary 14th, 2021
Read All

Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

By Dr. Matthew Watson

HOUSTON, Feb. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in a public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Read more:
Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

To Read More: Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock
categoriaGlobal News Feed commentoComments Off on Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock | dataFebruary 14th, 2021
Read All

Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx

By Dr. Matthew Watson

Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx

Continue reading here:
Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx

To Read More: Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx
categoriaGlobal News Feed commentoComments Off on Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx | dataFebruary 14th, 2021
Read All

Neck Hammock Reviews – Does this gadget really help? – Product Review by Mike Vaughn

By Dr. Matthew Watson

Follow this link:
Neck Hammock Reviews – Does this gadget really help? – Product Review by Mike Vaughn

To Read More: Neck Hammock Reviews – Does this gadget really help? – Product Review by Mike Vaughn
categoriaGlobal News Feed commentoComments Off on Neck Hammock Reviews – Does this gadget really help? – Product Review by Mike Vaughn | dataFebruary 14th, 2021
Read All

Page 3«..2345..1020..»